Skip to main content
. 2021 Nov 20;23:560–570. doi: 10.1016/j.omto.2021.11.010

Figure 6.

Figure 6

A summary diagram outlining the regulatory network of SOS1 in CML

Targeting the inhibition SOS1 using siRNA arrested the cell cycle by depressing the PI3K-AKT signal pathway and increased drug sensitivity or overcame drug-resistance by promoting the expression of SLC22A4. BAY-293 is an inhibitor of SOS1, which blocks Ras activation and improves imatinib response through the expression of SLC22A4.